News

Celcuity Showcases Promising Phase 3 Data at ESMO Congress

Celcuity Showcases Promising Phase 3 Data at ESMO Congress

Celcuity's Presentation of VIKTORIA-1 Trial Results

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company dedicated to developing targeted oncology therapies, is thrilled to announce its participation at the significant European Society of Medical Oncology (ESMO) Congress. During this esteemed event, Celcuity will share groundbreaking findings from its pivotal Phase 3 VIKTORIA-1 trial.

Details of the Late Breaking Oral Presentation

This important presentation, focusing on the PIK3CA wild-type cohort of the VIKTORIA-1 trial, is scheduled for October 18, 2025. Attendees can expect in-depth insights regarding the efficacy and safety of the innovative combination therapy involving gedatolisib.

Presentation Title and Timing

The oral presentation is titled:
Gedatolisib + fulvestrant ± palbociclib vs fulvestrant in patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1
Abstract Number: 3535
Session Title: Proffered paper session 1: Breast Cancer, metastatic
Date: October 18, 2025
Time: 10:15 am – 11:45 am CEST

Significance of the VIKTORIA-1 Trial

The VIKTORIA-1 trial is crucial as it evaluates the effectiveness of gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor, used in conjunction with fulvestrant and optional palbociclib for patients dealing with HR+/HER2- advanced breast cancer. By comprehensively targeting the PAM pathway, gedatolisib presents a noteworthy advancement compared to other treatments that only address PI3K?, AKT, or mTORC1 individually. The trial has already concluded enrollment for the PIK3CA wild-type cohort, yet continues to seek participants for the PIK3CA mutant cohort, marking a pivotal moment in breast cancer treatment research.

Further Expansions in Clinical Research

Moreover, Celcuity is not stopping at VIKTORIA-1. The company is actively conducting additional studies, such as the Phase 1/2 CELC-G-201 trial, which investigates the combination of gedatolisib and darolutamide in patients with metastatic castration-resistant prostate cancer. Another trial, the VIKTORIA-2 study, aims to assess the potential of gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2- advanced breast cancer.

About Celcuity: Innovations in Cancer Treatment

Celcuity Inc. prioritizes developing targeted therapies to enhance the lives of cancer patients. With a robust pipeline centered around the unique properties of gedatolisib, Celcuity strives to meet the pressing needs of patients battling various solid tumors. Their commitment to research and development is driven by a passion for unearthing innovative solutions in the oncology space. For more information, you can visit www.celcuity.com.

Frequently Asked Questions

What is the VIKTORIA-1 trial?

The VIKTORIA-1 trial evaluates the combination of gedatolisib and fulvestrant in treating patients with HR+/HER2- advanced breast cancer.

When will the results from the VIKTORIA-1 trial be presented?

The results will be presented on October 18, 2025, during a session at the ESMO Congress.

What is gedatolisib?

Gedatolisib is a novel pan-PI3K and mTORC1/2 inhibitor that targets the PAM pathway, differentiating itself from other therapies.

What are the implications of the VIKTORIA-1 trial?

This trial could provide critical insights into the efficacy of gedatolisib combined with fulvestrant for treating advanced breast cancer.

How can I learn more about Celcuity's trials?

Further details regarding Celcuity’s ongoing clinical trials can be found on their website at www.celcuity.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Perfect Companion Expands Amid Ohio's Growing Elderly Needs

Updated Category News Views 50

Riding the Aging Wave in Columbus The Perfect Companion is no stranger to the ups and downs of the eldercare industry. Celebrating five years in Columbus, this eldercare outfit's trying to pull off what many can't—a solid expansion in a landscape where finding reliable home care employees is about as easy as pulling teeth. But here they are, aiming to hire 25 more...

Continue Reading
Nektar Therapeutics Gears Up for Q3 Financial Reveal

Updated Category News Views 34

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Continue Reading
Sinopec's Bold African Moves: Sustainability and WE17

Updated Category News Views 18

A Bold African Initiative Alright, folks, let's get into the nitty-gritty of Sinopec's game plan in Africa. There's something to be said about a behemoth like Sinopec rolling out a sustainability report with real substance. We're looking at 33 projects across 16 countries, $5.7 billion in investments. Now, that's not just pocket change. Economic Muscle and Environmental...

Continue Reading
Antibiotic Overuse for Sinus Infections Costs Billions

Updated Category News Views 31

Sinus Infections: A Case of Excess Prescriptions You'd think with all the guidelines, doctors would've nailed the sinusitis treatment by now. But nope—antibiotic overuse remains alive and kicking. A fresh dig from Motive Medical Intelligence shows that more than three-quarters of primary care clinicians are quick to hand out antibiotics for acute sinusitis. So here we...

Continue Reading
SK hynix Hits $104 Trillion in Revenue, Boosts Dividends

Updated Category News Views 27

Phenomenal Financial Benchmark You gotta give it to SK hynix. They've just blown past that 100 trillion won ceiling like it's a minor bump on the highway. For folks tracking big numbers in memory semiconductors, this is fireworks-worthy. We're talking 104.6155 trillion won in revenue, a solid 83.3338 trillion won in operating profit, and a 39.7756 trillion won net profit....

Continue Reading
YUPRO Eases Internships: Streamlining Workforce Growth

Updated Category News Views 53

Paving the Way for Workforce Sustainability In the rat race of talent acquisition, YUPRO Placement dropped a bombshell with their SKILLS-TO-STAFF™ program. Business folks, this one’s for you if the idea of picking through resumes makes your head spin—it's simplifying the management of those pesky yet vital internship programs. Yeah, that’s right, no more drowning...

Continue Reading
Ad Council Expands Board, Taps Meta Exec as Vice Chair

Updated Category News Views 114

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Continue Reading
Le Mars Transload Expands: Rail Investment Heats Up

Updated Category News Views 20

There's a new rail story shaking up the industry—Le Mars, Iowa, is expanding its Transload Center. Look, it's not often a city with just over 10,000 souls makes waves on the logistics scene, but that’s exactly what's happening in Le Mars. This story's got more than just tracks and trains—it's about jobs, economies, and a place proudly dubbed 'The Ice Cream Capital...

Continue Reading
Proterra's New Hire Targets Credit Expansion Ambitions

Updated Category News Views 101

In the high-stakes world of leveraged finance, it's not always easy to stand out. Yet here we are, with Proterra Investment Partners snagging a seasoned vet, Eric Rogowski, for their credit squad. This ain't just window dressing; we're talking about real moves to beef up Proterra’s credit origination capacity—especially in the food, beverage, and agribusiness sectors....

Continue Reading
LabWare Loop: A Game Changer for Lab Data Integrity

Updated Category News Views 37

Breaking Down Silos in Lab Environments When it comes to the controlled chaos of laboratory operations, data integrity is the name of the game. We're talking about a new way of doing things that doesn't demand a physics degree just to connect the dots between gizmos and databases. Enter LabWare Loop, a solution that's rewriting the data playbook by linking multi-vendor...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Short Interest Trends for Universal Health Services

Updated Category News Views 172

Understanding Short Interest Trends for Universal Health Services Universal Health Services (NYSE: UHS) has experienced a notable change in its short interest, with a decrease of 9.14% since its last report. Currently, the company has around 1.41 million shares sold short, equating to 3.28% of all available regular shares for trading. Given the current trading volume,...

Continue Reading
Experience the All-New Luxury at Four Seasons Hotel George V

Updated Category News Views 232

A Transformative Renovation at Four Seasons Hotel George V Four Seasons Hotel George V has unveiled a stunning transformation that has redefined luxury accommodation. This landmark hotel, located in the heart of Paris, has undergone an extensive renovation project that lasted three years, culminating in the revitalization of its 243 rooms and suites. Each of these spaces...

Continue Reading
PerioImplant Innovations Adopts SprintRay 3D Printing Tech

Updated Category News Views 6

In a world where technology is revolutionizing just about everything, dentistry isn’t about to lag behind. Enter PerioImplant Innovations of Bloomington making waves by embracing SprintRay’s 3D printing brilliance for temporary full-arch implant restorations. You can bet this move has put some fresh momentum behind dental practices in Bloomington, Illinois. What's the...

Continue Reading
Discover Top Health Care Stocks to Boost Your Portfolio

Updated Category News Views 152

The Potential of Undervalued Health Care Stocks The health care sector often presents unique opportunities for savvy investors looking to enhance their portfolios. With several stocks currently being labeled as oversold, investors may find it beneficial to investigate these undervalued companies. Identifying stocks with an unfavorable Relative Strength Index (RSI) can...

Continue Reading
Chicago Rivet & Machine Co. Reports Positive Q3 Financials

Updated Category News Views 166

Chicago Rivet & Machine Co.'s Third Quarter Financial Overview Chicago Rivet & Machine Co. (NYSE: CVR) has unveiled its financial results for the third quarter. This announcement brings valuable insights into the company's performance during this period. Summary of Financial Results In the reported quarter, total net sales reached an impressive $7,360,284, showcasing...

Continue Reading